139 related articles for article (PubMed ID: 38686946)
1. Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma.
Swellam M; Khalifa MK; Nageeb AM; Ezz El-Arab L; El-Mahdy M; El-Bahy K; Sayed Mahmoud M
Int J Immunopathol Pharmacol; 2024; 38():3946320241250294. PubMed ID: 38686946
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.
Skiriutė D; Vaitkienė P; Ašmonienė V; Steponaitis G; Deltuva VP; Tamašauskas A
J Neurooncol; 2013 Jul; 113(3):441-9. PubMed ID: 23624749
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
4. NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors.
Kolodziej MA; Weischer C; Reinges MH; Uhl E; Weigand MA; Schwarm FP; Schänzer A; Acker T; Quint K; Uhle F; Stein M
Anticancer Res; 2016 Mar; 36(3):887-97. PubMed ID: 26976975
[TBL] [Abstract][Full Text] [Related]
5. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
6. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
[TBL] [Abstract][Full Text] [Related]
8. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
9. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
10. The Impact of
Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
[No Abstract] [Full Text] [Related]
11. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
12. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
14. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.
Tepel M; Roerig P; Wolter M; Gutmann DH; Perry A; Reifenberger G; Riemenschneider MJ
Int J Cancer; 2008 Nov; 123(9):2080-6. PubMed ID: 18709645
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
16. N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma.
Vaitkiene P; Valiulyte I; Glebauskiene B; Liutkeviciene R
Diagn Pathol; 2017 Apr; 12(1):33. PubMed ID: 28390436
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients.
Kefayat A; Amouheidari A; Ghahremani F; Alirezaei Z
Cancer Med; 2021 Aug; 10(15):5154-5162. PubMed ID: 34250760
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Rosas-Alonso R; Colmenarejo-Fernandez J; Pernia O; Rodriguez-Antolín C; Esteban I; Ghanem I; Sanchez-Cabrero D; Losantos-Garcia I; Palacios-Zambrano S; Moreno-Bueno G; de Castro J; Martinez-Marin V; Ibanez-de-Caceres I
Clin Epigenetics; 2021 Mar; 13(1):52. PubMed ID: 33750464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
